604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II

Navtemadlin, a Novel MDM2 Inhibitor, Potentiated Venetoclax-Induced Antitumor Efficacy in TP53 Wild-Type Acute Myeloid Leukemia (AML)

Analysis of Tagraxofusp Activity in AML-Pdc As a Single Agent and in Combination with BCL2 Inhibitors

The PP2A-B56a Heterocomplex Regulates Response to Venetoclax Plus Azacitidine Treatment in AML

The UBE2J2/UBE2K-MARCH5 Ubiquitination Machinery Regulates Apoptosis in Response to Venetoclax in Acute Myeloid Leukemia

Differentiation State Plasticity As a Mechanism of BCL2 Inhibitor Resistance in Acute Myeloid Leukemia

A STAT3 Degrader Demonstrates Pre-Clinical Efficacy in Venetoclax Resistant Acute Myeloid Leukemia

Novel Inhibitors of MLLT1/3, a Critical Component of the Super-Elongation Complex (SEC), Target a Range of Molecularly Defined Acute Leukemias, with a

SHP2 Inhibition Overcomes Adaptive and Acquired Resistance to FLT3 TKI to Improve Efficacy Against FLT3/ITD AML

Spatial Response to Pivekimab Sunirine (IMGN632) In Vivo in a BPDCN Model

RASMULTI(ON) Inhibitor RMC-7977 Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 Inhibitors in AML Models

Delivery of a-Particles By a Human-Rat Chimeric CD82 Monoclonal Antibody Potently Inhibits the Proliferation of CD82-Expressing Acute Myeloid Leukemia

Potent in Vitro and In Vivo Efficacy of BYON4413, a Duba-Based Antibody-Drug Conjugate Targeting CD123 in Acute Myeloid Leukemia

IFN? Signaling in Acute Myeloid Leukemia Mediates Immunomodulation and Reveals Therapeutic Strategies

CD38-Directed, Single-Chain T Cell-Engager Targets Leukemia Stem Cells through IFN?-Induced CD38 Expression

Tasquinimod Improves Erythropoiesis and Mitigates Bone Loss in Myelodysplastic Mice

Anti-Leukemic Effects of CK1a Degrader As Monotherapy and in Combination with Targeted Drugs

Preclinical and Clinical Evidence for Erythroid-Stimulating Activity of RVU120 CDK8/19 Inhibitor in AML and MDS

Sgr-2921, a Potent CDC7 Inhibitor, Demonstrates Significant Anti-Leukemic Responses in Patient-Derived AML Models Representing Difficult-to-Treat Dise

Prediction of PP2A Holoenzymes Guided By the Structural Characterization of Methylation Independent PP2A Assembly

PRC2-Mediated Apoptosis Evasion Is a Therapeutic Target of MDS/AML Harboring Inv(3)/t(3;3) and -7

Mitophagy As a Novel Cell-Protective Mechanism Against Mitochondrial Ferroptosis in Acute Myeloid Leukemia

AML Drug Tolerant Persister (DTP) Cells Survive Chemotherapy By Transiently Altering Cellular Lipidomics to Increase Plasma Membrane Rigidity, but Als

Tgrx-678, a Novel Allosteric Inhibitor of BCR-ABL1, Demonstrates Preclinical Anti-Leukemia Activity, High Oral Bioavailability and Synergism with Pona